Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 11 of 41
Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage
NCT07662174
Behavioral Economics to Implement Nutrition Ranking in Food Pantries
NCT05854212
The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation
NCT07323446
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol A
NCT07685028
taVNS Treatment for Fibromyalgia
NCT04777500
The Care for America's Aging Study
NCT06021704
ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
NCT05629442
Inhaled Nitric Oxide in Severe Obesity
NCT06675435
Developing Resiliency and Exercise Using AI-based Messaging
NCT07225283
Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
NCT06791057
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
NCT07405190
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
NCT07247097
Social Identity Mapping for Adolescent Recovery
NCT07474207
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
NCT07010302
Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) for Treatment of Post-Traumatic Stress Disorder (PTSD)
NCT07526285
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
NCT07265739
A Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion
NCT07639827
Biodegradable Magnesium Screws for Unstable Ankle Fracture Surgery
NCT07693933
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
NCT07013435
Infliximab for Immune Checkpoint Inhibitor Associated AKI
NCT07683975
Digital Coach to Support Exposure Therapy Homework for Anxious Youth
NCT07666672
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
NCT07355335
Role of n On-contrast Chest CT (NCCT) Based CT V: Q in Patients With Acute Pulmonary Embolism (aPE)
NCT07527117
Cognitive-behavioral Therapy vs. Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder Part II
NCT07641205
Randomized Trial of Combination Treatment With Sofwave and Sculptra
NCT07342452
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
NCT07358195
PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP Persistence
NCT07335289
Radiation Treatment Plan Evaluation Learning Tool Pilot Project
NCT06115811
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B
NCT07600801
Polarization Sensitive Optical Coherence Tomography (PS-OCT) for Retinal Imaging
NCT02441777
Enhancing Cardiac Rehabilitation Attendance After Secondary Myocardial Infarction Through Clinician Messaging and Motivational Calls
NCT07485491
Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques
NCT06957821
Resiliency Intervention for Patients With ALS and Their Care-Partners
NCT06968468
PET/MRI of Primary Sclerosing Cholangitis
NCT06252610
The Coma Family Program (COMA-F): A Resilience Program for Caregivers of Patients With Severe Acute Brain Injury
NCT07331324
Early Intervention
NCT05326165
Wearable Ultrasound Patch for Breast Imaging
NCT07186491
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
NCT07496463
Assessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus
NCT07450716
CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
NCT07077083
Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)
NCT07145866
PDT For Induction Therapy For Head And Neck Cancer
NCT07214987
Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency
NCT06866119
Resilient Families Feasibility Trial
NCT07383948
Enhancing Recovery Capital Amid Opioid Use Disorder Pharmacotherapy: A Pilot Randomized Trial
NCT05245513
Mindfulness-based Cognitive Therapy for the Chronic Pain-early Cognitive Decline Co-morbidity Among Older Black Individuals in the Community; The Feeling of Being Open Pilot
NCT07210398
Investigating the Relationship Between Glycemia and Sleep in Adults With Cystic Fibrosis-Related Diabetes
NCT06700889
Mindfulness-based Cognitive Therapy for the Chronic Pain-depression Co-morbidity Among Older Black Adults in the Community; The Quiet Focus Open Pilot
NCT07336342
Resiliency Programming for Caregivers of Children With Learning and Attentional Difficulties
NCT06492278
Predictive Analytics and Computer Visualization Enhances Patient Safety to Prevent Falls
NCT06339125
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.